Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dieter Meier

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
European Journal of Medicinal Chemistry|August 6, 2019
Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activityClaudia Lienau, Tobias Gräwert, Leandro A Alves Avelar, et al.
Brain : a Journal of Neurology|September 29, 2016
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's diseaseWolfgang Wrasidlo, Igor F Tsigelny, Diana L Price, et al.
Lancet (London, England)|May 18, 2010
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsKennedy R Lees, Erich Bluhmki, Rüdiger von Kummer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
European Journal of Medicinal Chemistry|August 6, 2019
Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activityClaudia Lienau, Tobias Gräwert, Leandro A Alves Avelar, et al.
Brain : a Journal of Neurology|September 29, 2016
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's diseaseWolfgang Wrasidlo, Igor F Tsigelny, Diana L Price, et al.
Lancet (London, England)|May 18, 2010
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsKennedy R Lees, Erich Bluhmki, Rüdiger von Kummer, et al.
Pageof 4